After 8 months on enzalutamide, a 75-year-old patients with metastatic castration-resistant prostate cancer showed a PSA level of 60.7 ng/mL, enlargement of
known pelvic lymph nodes, and progressive disease.
A 51-year-old man presented with worsening fatigue on exertion and pallor, with an ECOG performance score of 1. He eventually received a diagnosis of stage II standard-risk multiple myeloma after testing and examination.
A 75-year-old patient with metastatic castration resistant prostate cancer experienced an increase hip pain and urinary frequency 12 months after external beam radiation therapy plus androgen deprivation therapy.